Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib and Nivolumab in Advanced NSCLC
NCT05022394Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Feb 2021
01
Overview
A Phase 2 trial of sapanisertib in non-small cell lung carcinoma (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Feb 2021; status: withdrawn.
02
Drugs
sapanisertib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05022394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022394.